Skip to main content

8 Result(s)

within Sarah Davis Remove this filter Health Economics Remove this filter

and

  1. No Access

    Article

    Pirfenidone for Treating Idiopathic Pulmonary Fibrosis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    The National Institute for Health and Care Excellence (NICE) published guidance on the use of pirfenidone (Esbriet®, Roche) for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in 2013. NICE ...

    Sarah Davis, Rachid Rafia, Christopher Carroll, Jean Hamilton… in PharmacoEconomics (2019)

  2. Article

    Open Access

    Correction to: Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study

    The original article can be found online.

    Matthew Franklin, Sarah Davis, Michelle Horspool, Wei Sun Kua… in PharmacoEconomics (2019)

    Download PDF (359 KB) View Article

  3. No Access

    Article

    Obinutuzumab with Bendamustine for Treating Follicular Lymphoma Refractory to Rituximab: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

    As part of its single technology appraisal process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of obinutuzumab (Roche) to submit evidence on its clinical and cost ...

    Rachid Rafia, Abdullah Pandor, Sarah Davis, John W. Stevens… in PharmacoEconomics (2018)

  4. No Access

    Article

    Validation of a DICE Simulation Against a Discrete Event Simulation Implemented Entirely in Code

    Modeling is an essential tool for health technology assessment, and various techniques for conceptualizing and implementing such models have been described. Recently, a new method has been proposed—the discret...

    Jörgen Möller, Sarah Davis, Matt Stevenson, J. Jaime Caro in PharmacoEconomics (2017)

  5. Article

    Open Access

    Economic Evaluations Alongside Efficient Study Designs Using Large Observational Datasets: the PLEASANT Trial Case Study

    Large observational datasets such as Clinical Practice Research Datalink (CPRD) provide opportunities to conduct clinical studies and economic evaluations with efficient designs.

    Matthew Franklin, Sarah Davis, Michelle Horspool, Wei Sun Kua… in PharmacoEconomics (2017)

    Download PDF (625 KB) View Article

  6. No Access

    Article

    Sipuleucel-T for the Treatment of Metastatic Hormone-Relapsed Prostate Cancer: A NICE Single Technology Appraisal; An Evidence Review Group Perspective

    The National Institute for Health and Care Excellence (NICE) invited Dendreon, the company manufacturing sipuleucel-T, to submit evidence for the clinical and cost effectiveness of sipuleucel-T for asymptomati...

    Emma L. Simpson, Sarah Davis, Praveen Thokala, Penny R. Breeze… in PharmacoEconomics (2015)

  7. No Access

    Article

    Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective

    The National Institute for Health and Care Excellence (NICE) invited Boehringer Ingelheim GmbH, the manufacturer of alteplase, to submit evidence for the clinical and cost-effectiveness of alteplase for the pr...

    Michael Holmes, Sarah Davis, Emma Simpson in PharmacoEconomics (2015)

  8. No Access

    Article

    Golimumab for the Treatment of Rheumatoid Arthritis After the Failure of Previous Disease-Modifying Antirheumatic Drugs: A NICE Single Technology Appraisal

    As part of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process, the manufacturer of golimumab (Simponi®; Merck Sharp & Dohme, USA) was invited to submit evid...

    Jonathan Tosh, Rachel Archer, Sarah Davis, Matt Stevenson… in PharmacoEconomics (2013)